New Study from SiCORE-MSB & SiMPC Uncovers Plasma Metabolomic Markers in EGFR-Mutated Lung Cancer

🎉 Congratulations to Assoc. Prof. Dr. Sakda Khoomrung, Dr. Kwanjeera Wanichthanarak and the SiCORE-MSB & SiMPC team, Faculty of Medicine Siriraj Hospital, Mahidol University, on their latest publication in the Computational and Structural Biotechnology Journal (October 3, 2025):
“Plasma metabolomic analysis in Thai EGFR-mutated non-small cell lung cancer patients.”
📖 Read here 👉 ScienceDirect Link https://www.sciencedirect.com/science/article/pii/S200103702500412X

🧬 Study Highlights
This study demonstrates that plasma metabolomics can distinguish NSCLC (non-small cell lung cancer) patients from healthy individuals — and further separate EGFR-mutated from wild-type cases.
Key metabolites such as glycine, tryptophan, and oxalic acid were identified as potential markers linked to EGFR mutations and drug resistance.

💡 Why It Matters
Metabolic signatures in Thai patients differ from those in Western populations, emphasizing the need for population-specific precision medicine to improve diagnosis and treatment strategies in lung cancer.

🔬 Next Steps
The team is expanding into lipid metabolomics and developing spatial metabolomics + transcriptomics approaches to identify early-stage biomarkers for lung cancer detection.